IL-21 has dual anti-tumor effects in mantle cell lymphoma, offering new hopes for a better therapy.
Since the signing of the National Cancer Act in 1971, the medical field has achieved significant progress in finding cures for certain types of cancer. Therapies against breast cancer and childhood leukemia have undergone major advances in the past four decades. However, when it comes to non-Hodgkin lymphoma (NHL), the struggle is still loud and clear. More than 60,000 Americans are diagnosed with NHL each year and the current estimates are 30% of these cases will not survive the disease.1